{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Li L"],"funding":["Co-funding Mechanism on Joint Laboratories with the CAS - KIZ-CUHK Joint Laboratory of Bio-resources and Molecular Research in Common Diseases"],"pagination":["395"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12731563"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["13(12)"],"pubmed_abstract":["<b>Background:</b><i>JAK/STAT</i> interferon signaling interacts with the <i>PI3K/AKT/mTOR</i> pathway to drive hepatocellular carcinoma (HCC) progression and metastasis. <i>RSAD2</i>, an interferon-inducible gene, is upregulated by the <i>PI3K/AKT/mTOR</i> pathway and serves as a key factor for metabolic reprogramming to promote stem-like properties of cancer stem cells and tumor proliferation. In patients with resected HCC, <i>RSAD2</i> upregulation showed an association with microvascular invasion, which is a proven risk factor for developing HCC metastasis. This clinical observation was compatible with preclinical findings. On the other hand, <i>RSAD2</i> upregulation has been reported to confer poor prognosis in breast and gastric cancers. However, further clinical study of <i>RSAD2</"],"journal":["Diseases (Basel, Switzerland)"],"pubmed_title":["Clinical Implications of Upregulated &lt;i&gt;RSAD2&lt;/i&gt; Gene Expression in Hepatocellular Carcinoma."],"pmcid":["PMC12731563"],"funding_grant_id":["JLFS/M-403/24"],"pubmed_authors":["Lee KF","Hui EP","Kwan TK","Tang NLS","Chan SL","Koh J","Yu SCH","Mo F","Chan LL","Li L","Johnson DR","Yeo W"],"additional_accession":[]},"is_claimable":false,"name":"Clinical Implications of Upregulated &lt;i&gt;RSAD2&lt;/i&gt; Gene Expression in Hepatocellular Carcinoma.","description":"<b>Background:</b><i>JAK/STAT</i> interferon signaling interacts with the <i>PI3K/AKT/mTOR</i> pathway to drive hepatocellular carcinoma (HCC) progression and metastasis. <i>RSAD2</i>, an interferon-inducible gene, is upregulated by the <i>PI3K/AKT/mTOR</i> pathway and serves as a key factor for metabolic reprogramming to promote stem-like properties of cancer stem cells and tumor proliferation. In patients with resected HCC, <i>RSAD2</i> upregulation showed an association with microvascular invasion, which is a proven risk factor for developing HCC metastasis. This clinical observation was compatible with preclinical findings. On the other hand, <i>RSAD2</i> upregulation has been reported to confer poor prognosis in breast and gastric cancers. However, further clinical study of <i>RSAD2</","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Dec","modification":"2026-05-27T03:18:15.249Z","creation":"2026-05-27T03:11:48.991Z"},"accession":"S-EPMC12731563","cross_references":{"pubmed":["41439936"],"doi":["10.3390/diseases13120395"]}}